2-(2,3-Dimethylphenylamino)-oxazoline | 23417-36-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,3-Dimethylphenylamino)-oxazoline
• 英文别名: 2-(2,3-Dimethylanilino)-2-oxazoline；N-(2,3-dimethylphenyl)-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 23417-36-9
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: CHRXVAHRMWEZBK-UHFFFAOYSA-N

物化性质

• 沸点：
  280.9±50.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(2-氯乙基)-3-(2,3-二甲基苯基)脲 在 KF on SiO₂ 作用下， 以 乙腈 为溶剂， 以56%的产率得到2-(2,3-Dimethylphenylamino)-oxazoline
  参考文献：
  名称：

  作为秋水仙碱结合位点的潜在不可逆性拮抗剂的芳香族尿素衍生物和生物等排体的烷基化能力和蛋白质特异性。

  摘要：

  已经显示出许多N-苯基-N'-（2-氯乙基）脲（CEU）通过与细胞内β-微管蛋白上秋水仙碱结合位点的共价结合而成为有效的抗有丝分裂剂。本交流旨在评估CEU的亲电2-氯乙基氨基部分对细胞生长的抑制作用以及作为秋水仙碱结合位点的不可逆拮抗剂的药物的特异性。为此，一些N-苯基-N'-（2-乙基）脲（EU），N-苯基-N'-（2-氯乙基）脲（CEU），N-芳基氨基-2-恶唑啉（OXA）制备了N-苯基-N'-（2-氯乙酰基）脲（CAU）衍生物，并测试了它们的抗增殖活性，对细胞周期的影响以及与β-微管蛋白的不可逆结合。欧盟衍生物缺乏抗增殖活性。CEU（2h-2i，2k，2l，OXA 3e，3h，3i，3k，3l，tBCEU和ICEU），OXA（3h，3i，3k，3l，tBOXA和IOXA）和CAU（4a-4m，tBCAU和ICAU）在三种肿瘤细胞系上的GI（50）在1.7和10microM之间。细胞毒

  DOI：

  10.1016/j.bmc.2007.04.028

文献信息

• Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
  申请人：Allergan

  公开号：US05580892A1

  公开（公告）日：1996-12-03

  A pharmaceutical composition, useful for treating animals of the mammalian species, including humans, to treat diseases and conditions which normally respond to treatment with alpha.sub.2 adrenergic agents, contains as its active alpha.sub.2 adrenergic agent ingredient one or more compounds of the formula ##STR1## where X is 0, S or NH; n is an integer with the values of 0, 1 or 2; when n is 0 then R.sub.1 is lower alkyl having 1 to 6 carbon atoms and R.sub.2 is H or lower alkyl having 1 to 6 carbon atoms; when n is 1 or 2, then R.sub.1 and R.sub.2 both are methylene (CH.sub.2), or methylene substituted with an R.sub.5 group where R.sub.5 is lower alkyl of 1 to 6 carbons; R.sub.3 and R.sub.4 independently are H or lower alkyl having 1 to 6 carbons; R.sub.6 is H or lower alkyl of 1 to 6 carbons.

  一种制药组合物，用于治疗哺乳动物，包括人类，以治疗通常对α.sub.2肾上腺素能受体激动剂治疗有反应的疾病和症状，其活性α.sub.2肾上腺素能受体激动剂成分为下列化合物之一或多个：其中X为0、S或NH；n是一个整数，取值为0、1或2；当n为0时，R.sub.1为具有1至6个碳原子的低碳烷基，R.sub.2为H或具有1至6个碳原子的低碳烷基；当n为1或2时，R.sub.1和R.sub.2均为亚甲基（CH.sub.2），或者亚甲基上取代有一个R.sub.5基团，其中R.sub.5为1至6个碳原子的低碳烷基；R.sub.3和R.sub.4独立地为H或具有1至6个碳原子的低碳烷基；R.sub.6为H或具有1至6个碳原子的低碳烷基。
• Method for reducing or maintaining intraocular pressure in the mammalian
  申请人：Allergan, Inc.

  公开号：US05252595A1

  公开（公告）日：1993-10-12

  A pharmaceutical composition, preferably ophthalmic solution or ophthalmic suspension, useful for treating animals of the mammalian species, including humans, to reduce or maintain intraocular pressure in the eye contains as its pharmacologically active ingredient one or more compounds of the formula ##STR1## where X is O, S or NH; n is an integer with the values of 0, 1 or 2; when n is 0 then R.sub.1 is lower alkyl having 1 to 6 carbon atoms and R.sub.2 is H or lower alkyl having 1 to 6 carbon atoms; when n is 1 or 2, then R.sub.1 and R.sub.2 are methylene (CH.sub.2), or methylene substituted with an R.sub.5 group where R.sub.5 is lower alkyl of 1 to 6 carbons; R.sub.3 and R.sub.4 independently are H or lower alkyl having 1 to 6 carbons; R.sub.6 is H or lower alkyl of 1 to 6 carbons.

  一种制药组合物，首选为眼科溶液或眼科悬浮液，用于治疗哺乳动物物种，包括人类，以减少或维持眼内压力，其药理活性成分为公式##STR1## 中的一种或多种化合物，其中X为O，S或NH；n为0、1或2的整数；当n为0时，R.sub.1为1至6个碳原子的低碳基，R.sub.2为H或1至6个碳原子的低碳基；当n为1或2时，R.sub.1和R.sub.2为亚甲基（CH.sub.2），或亚甲基上取代有R.sub.5基团的亚甲基，其中R.sub.5为1至6个碳原子的低碳基；R.sub.3和R.sub.4独立地为H或1至6个碳原子的低碳基；R.sub.6为H或1至6个碳原子的低碳基。
• Method for using pharmaceutical compositions containing
  申请人：Allergan

  公开号：US05708015A1

  公开（公告）日：1998-01-13

  A pharmaceutical composition, useful for treating animals of the mammalian species, including humans, to treat diseases and conditions which normally respond to treatment with alpha.sub.2 adrenergic agents, contains as its active alpha.sub.2 adrenergic agent ingredient one or more compounds of the formula ##STR1## where X is O, S or NH; n is an integer with the values of 0, 1 or 2; when n is 0 then R.sub.1 is lower alkyl having 1 to 6 carbon atoms and R.sub.2 is H or lower alkyl having 1 to 6 carbon atoms; when n is 1 or 2, then R.sub.1 and R.sub.2 both are methylene (CH.sub.2), or methylene substituted with an R.sub.5 group where R.sub.5 is lower alkyl of 1 to 6 carbons; R.sub.3 and R.sub.4 independently are H or lower alkyl having 1 to 6 carbons; R.sub.6 is H or lower alkyl of 1 to 6 carbons.

  一种药物组合物，用于治疗哺乳动物物种，包括人类，以治疗通常对α.sub.2肾上腺素能受体药物治疗有反应的疾病和症状，其活性成分为一个或多个化合物，其化学式为 ##STR1## 其中X为O，S或NH; n为整数，取值为0、1或2; 当n为0时，R.sub.1为1至6个碳原子的低烷基，R.sub.2为H或1至6个碳原子的低烷基; 当n为1或2时，R.sub.1和R.sub.2都是亚甲基（CH.sub.2），或者是被R.sub.5基取代的亚甲基，其中R.sub.5是1至6个碳原子的低烷基; R.sub.3和R.sub.4独立地是H或1至6个碳原子的低烷基; R.sub.6为H或1至6个碳原子的低烷基。
• USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Allergan

  公开号：EP0724439A1

  公开（公告）日：1996-08-07
• USE OF 2-(2ALKYLPHENYLAMINO)OXAZOLINES AND -THIAZOLINES FOR THE MANUFACTURE OF A MEDICAMENT WITH ALPHA 2 ADRENERGIC EFFECT
  申请人：Allergan Sales, Inc.

  公开号：EP0724439B1

  公开（公告）日：2003-04-09